Shares of Mirna Therapeutics (NASDAQ: MIRN) dropped 23% after the company announced its definitive merger agreement with Synlogic, Inc. Per the agreement, Synlogic will merge with a wholly owned subsidiary of Mirna in an all-stock transaction. The merged company will focus on advancing Synlogic’s drug discovery and development platform for Synthetic Biotic medicines and operate under the Synlogic name. Synlogic also recently closed a $42 million Series C preferred stock financing from leading biotechnology investors to finance the merged company. “Following a thorough review of strategic alternatives, we are delighted to announce this transaction with Synlogic, which we believe is in the best interest of Mirna’s stockholders,” Mirna president and CEO Paul Lammers, M.D., M.Sc., stated in the news release.
To view the full press release, visit: http://nnw.fm/8bX34
About Mirna
Mirna is a biopharmaceutical company that has focused on the development of microRNA-based oncology therapeutics. Mirna’s first product candidate, MRX34, the first microRNA mimic to enter clinical development in oncology, was studied as a single agent in a multicenter phase 1 clinical trial. In September 2016, Mirna voluntarily halted enrollment and dosing in the clinical study following multiple immune-related serious adverse events (SAEs) observed in patients dosed with MRX34 over the course of the trial. Subsequently, the U.S. Food and Drug Administration (FDA) notified the company that the Investigational New Drug (IND) Application for MRX34 was placed on full clinical hold. The company has since closed the IND and focused on evaluating strategic alternatives, including the possibility of a merger or sale of the company. For more information, visit www.mirnatherapeutics.com.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
